非ホジキンリンパ腫 大韓民国 の治療 — 費用 2026

South Korea reports high Non-Hodgkin lymphoma success rates with a 10-year survival of nearly 79.2% at top institutions. Major Seoul hospitals achieve 85% to 90% remission for early-stage cases. Advanced protocols like R-CHOP show an 84.2% complete remission rate for diffuse large B-cell lymphoma.

• Success rates: Remission reaches 85% to 90% in early-stage Non-Hodgkin lymphoma patients.
• Specialized outcomes: Treatment for NK/T-cell lymphoma subtypes shows success in 71% to 78% of cases.
• Clinical volume: Asan Medical Center performs over 65,000 operations annually with high oncology expertise.
• Digital accuracy: Seoul National University Bundang Hospital uses the BESTcare system to prevent medical errors.

Bookimed Expert Insight: Clinical volume is the strongest indicator of success for complex blood cancers in Korea. Leading centers like Samsung Medical Center serve over 2 million patients yearly. This massive scale allows doctors to maintain specialized proficiency in rare lymphoma subtypes that smaller facilities rarely treat.

Patient Consensus: Patients value the rapid diagnostic speed in Seoul, where biopsy reviews and imaging often finish in days. Many note that choosing a major university hospital is vital for accessing the latest specialized hematology teams.

Korean tertiary hospitals actively use modern CAR-T cell therapy for relapsed or refractory Non-Hodgkin lymphoma. Specialized facilities like Samsung Medical Center and Asan Medical Center provide these personalized treatments. These centers utilize commercial therapies like Kymriah for patients with limited options.

• Available therapies: Centers use commercial CAR-T products like Tisa-cel for specific B-cell lymphomas.
• Success rates: Korean oncology reports show response rates between 70% and 90% for blood cancers.
• Hospital volume: Samsung Medical Center treats over 2,000,000 patients annually with advanced cancer protocols.
• Patient safety: SNUBH uses the BESTcare digital system to enhance therapy safety and effectiveness.

Bookimed Expert Insight: While several Korean hospitals hold JCI or KOIHA accreditation, CAR-T therapy requires unique infrastructure. Asan Medical Center and Severance Hospital manage massive patient volumes, with Severance seeing 1.6 million outpatients annually. This high volume allows these teams to maintain specialized cells labs required for complex CAR-T processing. When choosing a facility, confirm they handle the entire process from cell collection to toxicity monitoring in-house.

Patient Consensus: Patients note that major hospitals in Seoul organize workups very quickly compared to other countries. They emphasize that this therapy is usually a last-line option after standard chemotherapy or transplants fail.

Samsung Medical Center, Seoul National University Hospital, and Asan Medical Center are leading facilities for Non-Hodgkin lymphoma treatment in South Korea. These centers hold JCI and KOIHA accreditations. They offer advanced therapies like allogeneic bone marrow transplantation and specialized oncology care in Seoul.

• Bone marrow transplant: Specialized allogeneic and autologous transplants are available at major Seoul hospitals.
• Advanced diagnostics: Centers provide cytogenetic analysis and sentinel lymph node biopsies for precise staging.
• Hospital capacity: Asan Medical Center features over 2,700 beds for complex inpatient lymphoma care.
• Clinical volume: Severance Hospital serves 4,000,000 patients annually using vast hematology-oncology expertise.

Bookimed Expert Insight: Samsung Medical Center and Asan Medical Center consistently handle the highest surgical and patient volumes in Korea. Samsung manages over 45,000 operations annually. Asan performs over 65,000 yearly. This massive volume ensures their oncology teams have deep experience in rare lymphoma subtypes.

Patient Consensus: Patients note it is essential to bring original pathology slides and imaging to Seoul for re-review. Selecting a center with dedicated English-language coordination simplifies the complex treatment process.

Treatment for non-Hodgkin's lymphoma in South Korea typically begins within 1 to 2 weeks after diagnostics are complete. Specialists at major Seoul centers prioritize aggressive cases. Therapy starts after bone marrow punctures, PET-CT scans, and pathology reviews finalize the specific lymphoma subtype and staging.

• Diagnostic phase: Comprehensive testing including biopsy and cytogenetic analysis often takes 5–7 days.
• Treatment initiation: Chemo usually begins immediately once the oncology team locks the protocol.
• Hospital capacity: Large facilities like Asan Medical Center manage over 65,000 annual operations.
• Aggressive cases: High-growth lymphomas may trigger immediate hospitalization for urgent steroid or chemotherapy.

Bookimed Expert Insight: While patients often focus on the treatment start date, our data shows the most critical time-saver is choosing a digital-integrated hospital. Seoul National University Bundang Hospital uses the BESTcare system to sync pathology and imaging instantly. This connectivity often shaves 3 days off the pre-treatment wait compared to manual data transfers.

Patient Consensus: Patients note that major university hospitals in Seoul provide the fastest path to treatment. They emphasize that the real wait occurs during pathology review and suggest having a single coordinator to sync different tests.

Most oncohematologists in major South Korean tertiary hospitals speak functional English. These specialists utilize English for medical research and global conferences. Large Seoul-based centers like Samsung Medical Center and Severance Hospital maintain dedicated international departments to ensure clear communication during complex lymphoma treatments.

• Academic proficiency: Doctors use English for international research and hematology textbooks.
• International departments: JCI-accredited centers provide bilingual coordinators for non-English fluent staff.
• Digital support: Systems like SNUBH's BESTcare use English medical terminology for records.
• Clinical documentation: Major oncology departments routinely accept and provide reports in English.

Bookimed Expert Insight: While South Korea ranks 4th globally for patient requests, our data shows a concentration of English proficiency in major university hospitals. Centers like Asan Medical Center handle over 182,000 patients annually and prioritize international services. Choosing a hospital with JCI or GHA accreditation ensures a structured communication framework for international oncology patients.

Patient Consensus: Patients note that while doctors understand technical medical terms well, administrative staff might not. They highly recommend using hospital-provided interpreters and bringing all previous pathology reports in English to avoid misunderstandings.

South Korea reports high survival rates for Non-Hodgkin lymphoma. The overall 5-year relative survival across the population reaches approximately 70%. Marginal Zone Lymphoma shows an 88% survival rate. High-volume Seoul centres like Samsung Medical Center use proton therapy to improve outcomes while sparing healthy tissue.

• Subtype survival: Marginal Zone Lymphoma reaches 88% while Follicular Lymphoma maintains a 79% survival rate.
• Stage 1 outcomes: Early-stage diagnosis typically results in a 5-year survival rate of up to 88%.
• Advanced stage: Even Stage 4 patients often see 5-year survival rates exceeding 60% in Korea.
• Treatment volume: Seoul National University Hospital has completed over 1,800 bone marrow transplants for haematology patients.

Bookimed Expert Insight: South Korea scales complex care through specialised cancer hubs. Samsung Medical Center operates Asia's largest cancer centre with 17 specific departments. This high volume lets doctors specialise in rare lymphoma subtypes. Data shows Severance Hospital and Asan Medical Center each perform over 40,000 operations annually. This immense clinical experience directly correlates with the country's improved survival statistics for aggressive B-cell lymphomas.

Patient Consensus: Patients highlight that remission at the 2-year mark is a critical milestone in South Korea. They note that the exact lymphoma subtype and molecular markers often influence individual outlooks more than the initial stage of the disease.

South Korean medical centres provide Non-Hodgkin lymphoma treatments including R-CHOP chemotherapy, bone marrow transplants, and targeted therapies. Specialised facilities in Seoul utilise proton beam therapy and CAR-T cell protocols for complex cases. Most treatments are delivered within JCI-accredited hospitals. These hospitals treat thousands of international patients annually.

• Chemotherapy regimens: Clinics commonly administer R-CHOP and 5-day continuous R-EPOCH infusions.
• Transplant types: Specialists perform autologous and allogeneic bone marrow transplants for recurring cases.
• Advanced radiation: Centres offer proton beam therapy and tomotherapy to target tumours precisely.
• Diagnostic precision: Teams use PET-CT and sentinel lymph node biopsies for accurate staging.

Bookimed Expert Insight: South Korea has significant capacity for complex blood cancers. Seoul National University Hospital alone has completed over 1,800 bone marrow transplants. Standard R-CHOP is common. However, major centres like Samsung Medical Center house 17 disease-specific departments. This specialisation allows oncologists to offer dose-adjusted chemotherapy for older patients. This balances effective treatment with manageable side effects.

Patient Consensus: Patients find that Korean hospitals require detailed pathology records and scans before confirming a plan. They often note that professional interpreters help manage the intensive schedule. This schedule involves chemotherapy infusions and recovery periods in Seoul.

South Korean doctors determine Non-Hodgkin lymphoma treatment through rapid multi-specialist reviews and molecular diagnostics. Teams of haematologists, pathologists, and radiologists use PET-CT and bone marrow analysis. They typically finalise a tailored plan involving chemotherapy, immunotherapy, or transplants within 7 days.

• Multidisciplinary approach: Haematologists and oncologists collaborate to match therapy to specific lymphoma subtypes.
• Diagnostics: Doctors use PET-CT and cytogenetic testing to distinguish aggressive from indolent cases.
• Subtype-specific plans: Indolent cases may require observation, while aggressive types involve intensive chemo-immunotherapy.
• Transplant capacity: Centres like Seoul National University Hospital have completed 1,800+ bone marrow transplants.
• High-volume expertise: Asan Medical Center performs 65,000+ operations annually, providing deep experience in complex care.

Bookimed Expert Insight: South Korean oncology centres lead in digital integration. Samsung Medical Center and Seoul National University Hospital use real-time digital imaging and EHR systems. This allows pathology results to reach the multidisciplinary team instantly. For Australian patients, this means treatment often starts days faster. It is faster than traditional paper-based hospital systems.

Patient Consensus: Patients note that Korean specialists distinguish slow-growing from aggressive subtypes. They do this before recommending intensive therapy. They emphasise bringing original pathology slides from Australia. This speeds up staging and confirms the exact diagnosis.

South Korean hospitals are exceptionally well-equipped for Non-Hodgkin’s lymphoma. They feature JCI-accredited cancer centres and CAR-T cell therapy. Facilities like Samsung Medical Center and Asan Medical Center integrate digital imaging with precision oncology. Most major centres provide rapid diagnostic workups and complex stem cell transplantations.

• Advanced therapies: Major hospitals provide CAR-T cell therapy, proton beam therapy and allogeneic stem cell transplantation.
• Clinical volume: Asan Medical Center performs over 65,000 surgeries annually. It manages high-volume haematologic malignancy cases.
• Diagnostic precision: Sites like SNU Bundang Hospital use PET-CT and BESTcare digital systems to improve accuracy.
• Research partnerships: Severance Hospital collaborates with MD Anderson Cancer Center to implement world-leading oncology protocols.

Bookimed Expert Insight: Many Australian patients look for specific technologies. However, South Korea’s real advantage is the integration of digital hospital systems like BESTcare. Clinics such as SNU Bundang Hospital have been fully digital for decades. This allows oncohaematologists to share PET-CT and MRI data instantly across departments. This coordination often leads to starting intensive treatments faster than in traditional Western hospital settings.

Patient Consensus: Patients describe the cancer care at major Seoul university hospitals as fantastic. They note the efficient test setups and high-quality chemotherapy. Many recommend bringing full pathology reports and slides from Australia. This avoids repetitive testing delays in South Korea.

Clinical trials for Non-Hodgkin lymphoma are widely available in South Korea at major academic centres. Facilities like Seoul National University Hospital and Samsung Medical Center actively recruit for Phase 1 to 3 studies. These trials often investigate targeted therapies, immunotherapy, and bispecific antibodies for relapsed or refractory cases.

• Targeted therapies: Studies evaluate treatments including BTK inhibitors, monoclonal antibodies, and PI3K inhibitors.
• Specialised centres: Samsung Medical Center houses Asia's largest cancer centre with 17 disease-specific departments.
• High-volume expertise: Seoul National University Hospital has completed over 1,800 bone marrow transplants for patients.
• Global integration: Leading centres like Severance Hospital partner with MD Anderson and Johns Hopkins University.

Bookimed Expert Insight: Patients often focus on the largest hospitals. However, smaller university centres in Seoul also host trials. Data shows that institutions with international departments, like Soon Chun Hyang, have served 15,000+ patients. These centres often provide 24/7 interpreters. This makes complex trial protocols easier for Australian patients to navigate.

Patient Consensus: Patients note that major Seoul centres frequently run trials for aggressive subtypes like DLBCL. They suggest bringing full pathology reports early. This helps hospitals confirm trial eligibility and potential sponsorship before travel.

Patients do not stay in hospital throughout the entire treatment for Non-Hodgkin lymphoma in South Korea. Hospitalisation is usually reserved for intensive procedures like bone marrow transplants or CAR-T cell therapy. Standard chemotherapy typically follows a cycle-based outpatient schedule with rest periods in local accommodation.

• Treatment cycles: Chemo involves sessions every 2–3 weeks, often allowing travel between visits.
• Transplant stays: Bone marrow transplants require several weeks of inpatient isolation for safety.
• Initial diagnostics: Planning includes bone marrow puncture and PET-CT scans, usually as an outpatient.
• International support: Asan Medical Center provides coordinators to help manage logistics and transfers.
• Administrative steps: Centres like SNUH require record verification before starting cycles, taking several days.

Bookimed Expert Insight: While major Seoul clinics like Samsung Medical Center serve 2 million outpatients annually, admission policies depend on the specific protocol. Some clinics offer 'day admission' where patients receive treatment over 6–8 hours but do not stay overnight. This reduces costs significantly compared to full inpatient care while providing professional monitoring.

Patient Consensus: Patients note that continuous admission is rare. Most only stay in hospital for surgeries, isolation during immune dips, or the first chemotherapy cycle. Hospitals expect patients to go home or to a hotel to rest between treatments. So planning local accommodation near the hospital is essential.